Mr. Rashid Bux reports

BIOMARK ANNOUNCES THE U.S. PATENT AND TRADEMARK OFFICE GRANTED PATENT WITH CLAIMS COVERING ITS LUNG CANCER LIQUID BIOPSY ASSAY

Biomark Diagnostics Inc. has noted that the United States Patent and Trademark Office (USPTO) has issued U.S. patent No. 11,656,229, which was filed as a provisional on June 26, 2015, and titled "Method of Detecting Lung Cancer." The issued patent belongs to a larger family of patents on the company's biomarker panel for detecting lung cancer, and complements similar patents already approved in Japan and Canada, and pending in Europe and China.

"This is a pivotal moment for Biomark, and the timing is well synchronized with our planned commercialization of our early lung cancer screening assay slated for introduction in North America later this fiscal year," said Rashid Bux, chief executive officer and president of Biomark. Screening helps to detect cancer at an early stage, which can improve the long-term survival rate. There is an urgency to improve screening, affordability and accessibility globally. As a result, the global lung cancer screening market is expected to grow from approximately $2-billion in 2021 to over $4-billion by 2029. Mr. Bux adds: "Our pursuit in innovative molecular diagnostic assay development backed by proven science is yielding immense latent value, the intangible portion of our balance sheet. Biomark is well positioned to add additional patents to help address one of the most significant unmet needs in early cancer detection."

Cancer remains one of the leading causes of deaths in the world and the prevalence of the disease has been increasing. The growing awareness of lung cancer and an increasing government initiative regarding screening, early detection and management of lung cancer are anticipated to drive the global cancer diagnostics market in the upcoming years. Another key driver is the growing demand for liquid biopsy tests. Biomark's extensive portfolio of patents covering key products in this market creates shareholder value by giving the company both the freedom to operate and significant product differentiation.

About Biomark Diagnostics Inc.

Biomark is a liquid biopsy company developing a molecular diagnostics technology platform that leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improving cancer prognosis by allowing physicians to detect carcinomas in the presymptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. While the company's current focus is on the commercialization of its liquid biopsy test for early detection of lung cancer, it has plans to expand into other hard-to-detect and hard-to-treat cancers such as brain, ovarian and pancreatic.

We seek Safe Harbor.